Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.

Haas, Quentin; Markov, Nikita; Muerner, Lukas; Rubino, Viviana; Benjak, Andrej; Haubitz, Monika; Baerlocher, Gabriela M; Ng, Charlotte K Y; Münz, Christian; Riether, Carsten; Ochsenbein, Adrian F; Simon, Hans-Uwe; von Gunten, Stephan (2022). Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. Frontiers in immunology, 13, p. 996746. Frontiers Research Foundation 10.3389/fimmu.2022.996746

[img]
Preview
Text
fimmu-13-996746.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (8MB) | Preview

While inhibitory Siglec receptors are known to regulate myeloid cells, less is known about their expression and function in lymphocytes subsets. Here we identified Siglec-7 as a glyco-immune checkpoint expressed on non-exhausted effector memory CD8+ T cells that exhibit high functional and metabolic capacities. Seahorse analysis revealed higher basal respiration and glycolysis levels of Siglec-7+ CD8+ T cells in steady state, and particularly upon activation. Siglec-7 polarization into the T cell immune synapse was dependent on sialoglycan interactions in trans and prevented actin polarization and effective T cell responses. Siglec-7 ligands were found to be expressed on both leukemic stem cells and acute myeloid leukemia (AML) cells suggesting the occurrence of glyco-immune checkpoints for Siglec-7+ CD8+ T cells, which were found in patients' peripheral blood and bone marrow. Our findings project Siglec-7 as a glyco-immune checkpoint and therapeutic target for T cell-driven disorders and cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Faculty Institutions > Bern Center for Precision Medicine (BCPM)
09 Interdisciplinary Units > Microscopy Imaging Center (MIC)

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Haas, Quentin, Markov, Nikita, Mürner, Lukas Dominic, Rubino, Viviana, Benjak, Andrej, Haubitz, Monika, Bärlocher, Gabriela Maria, Ng, Kiu Yan Charlotte, Riether, Carsten, Ochsenbein, Adrian, Simon, Hans-Uwe, von Gunten, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1664-3224

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Pubmed Import

Date Deposited:

11 Oct 2022 10:41

Last Modified:

05 Dec 2022 16:26

Publisher DOI:

10.3389/fimmu.2022.996746

PubMed ID:

36211376

Uncontrolled Keywords:

CD8+ T cells Siglec-7 acute myeloid leukemia hypersialylation immune checkpoint sialoglycans tumor immunity and immunotherapy

BORIS DOI:

10.48350/173646

URI:

https://boris.unibe.ch/id/eprint/173646

Actions (login required)

Edit item Edit item
Provide Feedback